Medical Stocks

Becton Dickinson & Company Analysis – August 2015 Update $BDX

Benjamin Graham taught that Intelligent Investors must do a thorough fundamental analysis of investment opportunities to determine their intrinsic value and inherent risk.  This is best done by utilizing a systematic approach to analysis that will provide investors with a sense of how a specific company compares to another company or by reviewing the 10 Most Undervalued Companies for the Defensive Investor – August 2015.  By using the ModernGraham method one can review a company’s historical accomplishments and determine an intrinsic value that can be compared across industries.  What follows is a stock analysis showing a specific look at how Becton Dickinson & Company (BDX) fares in the ModernGraham valuation model.

Company Profile (obtained from Google Finance): Becton Dickinson and Co. is a global medical technology company engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The Company’s operations consist of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The BD Medical segment manufactures syringes, needles and other products used in a range of healthcare settings. The BD Diagnostics segment collects and transport diagnostics specimens. The BD Biosciences segment produces clinical research tools that aid discovery and development of new drugs and vaccines.

[level-free]

To read the details of this valuation, you must be logged in as a premium member. If you are not a premium member, please consider becoming one.

Premium members can view a full ModernGraham valuation of the company and have access to download a PDF version of the valuation for easy reference. Here is a free sample valuation pdf, and here is a post detailing what can be found within each individual company’s valuation.

[/level-free]
[level-mg-stocks-screens-subscriber]

Downloadable PDF version of this valuation:

ModernGraham Valuation of BDX – August 2015

Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

What kind of Intelligent Investor are you?

Defensive Investor; must pass 6 out of the following 7 tests.
1. Adequate Size of the Enterprise Market Cap > $2Bil Pass
2. Sufficiently Strong Financial Condition Current Ratio > 2 Fail
3. Earnings Stability Positive EPS for 10 years prior Pass
4. Dividend Record Dividend Payments for 10 years prior Pass
5. Earnings Growth Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end Pass
6. Moderate PEmg Ratio PEmg < 20 Fail
7. Moderate Price to Assets PB Ratio < 2.5 OR PB*PEmg < 50 Fail
Score
Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.
1. Sufficiently Strong Financial Condition Current Ratio > 1.5 Fail
2. Sufficiently Strong Financial Condition Debt to NCA < 1.1 Fail
3. Earnings Stability Positive EPS for 5 years prior Pass
4. Dividend Record Currently Pays Dividend Pass
5. Earnings Growth EPSmg greater than 5 years ago Pass

Stage 2: Determination of Intrinsic Value

EPSmg 5.50
MG Growth Estimate 0.97%
MG Value $57.33
Opinion Overvalued
MG Value based on 3% Growth $79.68
MG Value based on 0% Growth $46.71
Market Implied Growth Rate 9.08%
Current Price $146.53
% of Intrinsic Value 255.58%

Becton Dickinson & Company does not qualify for either the Enterprising Investor or the more conservative Defensive Investor.  The Defensive Investor is concerned with the low current ratio, and the high PEmg and PB ratios.  The Enterprising Investor is concerned with the level of debt relative to the current assets.  As a result, all Enterprising Investors following the ModernGraham approach based on Benjamin Graham’s methods should feel comfortable proceeding with further research into the company.

As for a valuation, the company appears to be overvalued after growing its EPSmg (normalized earnings) from $5.16 in 2012 to an estimated $5.50 for 2016.  This level of demonstrated earnings growth does not support the market’s implied estimate of 9.08% annual earnings growth over the next 7-10 years.  As a result, the ModernGraham valuation model, based on Benjamin Graham’s formula, returns an estimate of intrinsic value below the price.

The next part of the analysis is up to individual investors, and requires discussion of the company’s prospects.  What do you think?  What value would you put on Becton Dickinson & Company (BDX)?  Where do you see the company going in the future?  Is there a company you like better?  Leave a comment on our Facebook page or mention @ModernGraham on Twitter to discuss.

Stage 3: Information for Further Research

BDX charts August 2015

Net Current Asset Value (NCAV) -$62.92
PEmg 26.66
Current Ratio 1.40
PB Ratio 4.34
Dividend Yield 1.60%
Number of Consecutive Years of Dividend Growth 20

 

[/level-mg-stocks-screens-subscriber]

Useful Links:

ModernGraham tagged articles Morningstar
Google Finance MSN Money
Yahoo Finance Seeking Alpha
GuruFocus SEC Filings

Most Recent Balance Sheet Figures

Total Current Assets $6,303,000,000
Total Current Liabilities $4,517,000,000
Long-Term Debt $11,367,000,000
Total Assets $27,079,000,000
Intangible Assets $14,973,000,000
Total Liabilities $19,826,000,000
Shares Outstanding (Diluted Average) 214,928,000

Earnings Per Share History

Next Fiscal Year Estimate $4.44
Sep14 $5.99
Sep13 $6.49
Sep12 $5.59
Sep11 $5.62
Sep10 $5.49
Sep09 $4.99
Sep08 $4.46
Sep07 $3.49
Sep06 $2.93
Sep05 $2.77
Sep04 $1.77
Sep03 $2.07
Sep02 $1.79
Sep01 $1.49
Sep00 $1.49
Sep99 $1.04
Sep98 $0.90
Sep97 $1.15
Sep96 $1.06
Sep95 $0.90

Earnings Per Share – ModernGraham History

Next Fiscal Year Estimate $5.50
Sep14 $5.96
Sep13 $5.84
Sep12 $5.42
Sep11 $5.16
Sep10 $4.71
Sep09 $4.13
Sep08 $3.49
Sep07 $2.87
Sep06 $2.46
Sep05 $2.15
Sep04 $1.80
Sep03 $1.73
Sep02 $1.49
Sep01 $1.30
Sep00 $1.18
Sep99 $1.02

Recommended Reading:

Other ModernGraham posts about the company

30 Companies in the Spotlight This Week – 5/23/15
Becton Dickinson and Company Quarterly Valuation – May 2015 $BDX
34 Companies in the Spotlight This Week – 2/7/15
Becton, Dickinson and Company Quarterly Valuation – February 2015 $BDX
27 Companies in the Spotlight This Week – 11/8/14

Other ModernGraham posts about related companies

Align Technology Analysis – Initial Coverage $ALGN
Varian Medical Systems Inc Analysis – August 2015 Update $VAR
Psychemedics Corporation Analysis – August 2015 Update $PMD
C.R. Bard Inc. Analysis – August 2015 Update $BCR
Thermo Fisher Scientific Inc. Analysis – 2015 Update $TMO
Express Scripts Inc. Analysis – 2015 Update $ESRX
HCA Holdings Inc. Analysis – Initial Coverage $HCA
Henry Schein Inc. Analysis – Initial Coverage $HSIC
Medtronic Inc. Analysis – July 2015 Update $MDT
Quest Diagnostics Inc. Analysis – July 2015 Update $DGX

Disclaimer:

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  This article is not investment advice; any reader should speak to a registered investment adviser prior to making any investment decisions.  ModernGraham is not affiliated with the company in any manner.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back To Top